[CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka
Yoshiya
Y
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation; D017951:Antigen Presentation; D018951:Antigens, CD20 / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001323:Autoantibodies; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002986:Clinical Trials as Topic; D003095:Collagen Diseases / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D000069283:Rituximab; D014657:Vasculitis / Q000188:drug therapy
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D000069283:Rituximab